- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04415424
Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men (GoGoVax)
May 23, 2023 updated by: Kirby Institute
A Multi-centre Randomised Controlled Trial Evaluating the Efficacy of the Four-component Meningococcal B Vaccine, 4CMenB (Bexsero®), in the Prevention of Neisseria Gonorrhoeae Infection in Gay and Bisexual Men
This is a Phase 3, double-blinded, randomised placebo-controlled, multi-centred trial evaluating the efficacy of the four-component meningococcal B vaccine, 4CMenB (Bexsero®), in the prevention of Neisseria gonorrhoeae infection.The targeted population is 18-50 years-old men (cis and trans), trans women and non-binary people who have sex with men (hereafter referred to as Gay Bisexual Men+ [GBM+], either HIV-negative and taking pre-exposure prophylaxis [PrEP], or HIV-positive with undetectable viral load <200copies/ml and a cluster of differentiation 4 [CD4] count >350 cells/cmm) who have high N. gonorrhoeae incidence and are recommended by Australian guidelines to have regular, comprehensive sexual health screening.
730 participants will be enrolled and randomised 1:1 and stratified by clinical sites to receive two doses of 4CMenB vaccine or a matching placebo at 0 and 3 months by intramuscular injection.
Recruitment is for 12 months and all participants will be follow-up 3-monthly for a period of 2 years.
The trial aims to evaluate the efficacy of 4CMenB in the prevention of N. gonorrhoeae infection.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 3, double-blinded, randomised placebo-controlled, multi-centred trial evaluating the efficacy of the four-component meningococcal B vaccine, 4CMenB (Bexsero®), in the prevention of Neisseria gonorrhoeae infection.The target population for this trial is GBM+, either HIV-negative and on PrEP or HIV-positive, who had a diagnosis of gonorrhoea or infectious syphilis in the last 18 months (a key characteristic associated with greater gonorrhoea risk).
This population has the highest known gonococcal incidence and are recommended under Australian guidelines to attend clinics 3-monthly for comprehensive sexual health screening, including Nuclei acid amplification test (NAAT)-based screening of urine, and pharyngeal and anal specimens for N. gonorrhoeae infection.
730 participants will be enrolled and randomised 1:1 and stratified by clinical sites to receive two doses of 4CMenB vaccine or a matching placebo at 0 and 3 months by intramuscular injection.
Recruitment will occur over a 12-month period and all participants will be followed up 3-monthly over a period of 2 years.
Participants, their study clinicians and study researchers assessing the outcomes will be blinded to the treatment arm (vaccine or placebo).
Participants will be required to attend approximately 10 study visits.
Participants may attend additional visits if they have been diagnosed with gonorrhoea infection (symptomatic or asymptomatic) or have a postitive gonorrhoea NAAT test when they return for test of cure.
Potentially eligible individuals will be screened within 14 days of baseline (the visit when the first dose of study treatment is administered).
Randomisation can be conducted any time between screening and baseline.
Screening, randomisation and baseline can occur on the same day if the required HIV result(s) and drug kit (containing 4CMenB or placebo) are available for a participant in the clinic.
At screening, study clinicians will conduct the informed consent process with a participant and the informed consent will be signed by both the study clinician and the participant.
Eligibility criteria will be checked and a review of medical history (including vaccination history for 4CMenB, prior known meningococcal disease, recent history of sexually transmitted infections [STIs], history of taking PrEP [for HIV negative individuals] as well as antibiotic use in the last 3 months) will be conducted.
Routine blood, urine and swabs will be collected, and urine pregnancy test will be performed in participants with child-bearing potential.
Symptoms of urethritis, proctitis, epididymitis, and cervicitis/vaginitis will be documented.
At randomisation (which can occur anytime within screening an baseline), participants will be randomised to receive either the 4CMenB vaccine or the placebo.
At the baseline visit, research blood specimen and an oral mucosal exudate swab for immune responses testing will be collected before the administration of the first dose of the study treatment.
A 10-minute study questionnaire will be completed by the participants.
Participants will return to their study site 3 months after the first dose of study treatment to receive the second dose.
Prior to the treatment administration, urine pregnancy test (in participants with child-bearing potential) will be conducted.
Symptoms of urethritis, proctitis, epididymitis, and cervicitis/vaginitis will be documented.
History of antibiotic use in the last 3 months will also be collected.
If a participant has tested positive for gonorrhoea infection, routinely collected culture isolates and NAAT samples will be stored in a study research laboratory for phenotypic antimicrobial resistance (AMR) testing and genotyping.
Routine blood, urine and swabs will also be collected.
Adverse events and serious adverse events (SAEs) will be recorded but only SAEs will be entered into the study electronic data capture system, and reported to the Sponsor in real time.
Three-monthly visits will be conducted over a period of 2 years.
The study aims to evaluate the efficacy of 4CMenB in the prevention of N. gonorrhoeae infection.
Study Type
Interventional
Enrollment (Actual)
652
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Professor Kate Seib, BSc(Hon),PhD
- Phone Number: +617 55527453
- Email: k.seib@griffith.edu.au
Study Contact Backup
- Name: Ms Barbara Yeung, BHSc, MPH
- Phone Number: +612 93850879
- Email: byeung@kirby.unsw.edu.au
Study Locations
-
-
New South Wales
-
Parramatta, New South Wales, Australia, 2150
- Western Sydney Sexual Health Centre
-
Sydney, New South Wales, Australia, 2010
- Taylor Square Private Clinic
-
Sydney, New South Wales, Australia, 2000
- Sydney Sexual Health Centre
-
Sydney, New South Wales, Australia, 2050
- RPA Sexual Health
-
-
Queensland
-
Southport, Queensland, Australia, 4215
- Gold Coast Sexual Health Service
-
-
Victoria
-
Carlton, Victoria, Australia, 3053
- Melbourne Sexual Health Centre
-
Melbourne, Victoria, Australia, 3181
- Prahran Market Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Between 18 to ≤ 50 years of age
- Men (cis and trans), trans women and non-binary people who have had sex with at least one man in the last 6 months
- Diagnosis of gonorrhoea or infectious syphilis in the last 18 months
- Committed not to take doxycycline as prophylaxis for the duration of the trial
- Able to understand spoken and written English
- Willing and likely to comply with the trial procedures for 2 years
- Agree to be contacted via short message service (SMS)/phone/ email by the study team
AND EITHER
- HIV-negative (with an HIV negative antibody test within 4 months of screening) and taking HIV PrEP (daily PrEP or on-demand PrEP) within the last 4 months at the time of enrolment or
- HIV-positive and on an antiviral regimen, with an undetectable virus level of <200 copies/ml and a CD4 count >350 cells/cmm (to optimise the immune response to vaccine) within 12 months of screening
Exclusion Criteria:
- Have a previous history of vaccination for meningococcal B with 4CMenB
Have contraindications to receiving the meningococcal B vaccine which include:
- Anaphylaxis following a previous dose of any meningococcal vaccine
- Anaphylaxis following any vaccine component
- Are participating in biomedical prevention strategies for bacterial STIs (participation in diagnostic or treatment studies is not an exclusion)
- Are taking long-term (> 4 weeks) antibiotic for prophylaxis or treatment for acne, malaria, syphilis or other bacterial condition(s)
- Have defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency
- Are taking or will receive complement inhibitors such as eculizumab (a monoclonal antibody directed against complement component C5) or ravulizumab
- Have functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies, and congenital or acquired asplenia
- Have had a haematopoietic stem cell transplant
- Have any major unstable medical condition or therapy that may cause immune compromise (e.g. chemotherapy, radiation, corticosteroids [prednisone >5mg/day] within 14 days prior to screening)
- Documented allergy to latex and/or kanamycin
- Have prior known meningococcal disease
- Positive pregnancy test at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm A - 4CMenB vaccine
4CMenB vaccine will be administered as an intramuscular injection in 0.5 ml single-dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
|
A four-component meningococcal B vaccine
Other Names:
|
Placebo Comparator: Treatment arm B - placebo
Placebo will be administered as an intramuscular injection in 0.5 ml single dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
|
0.5 ml of 150 mmol sodium chloride (0.9% saline solution)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure whether the 4CMenB vaccine, when administered in a 2-dose regimen at 0 and 3 months, changes the incidence of the first episode of N. gonorrhoeae.
Time Frame: From Month 4 to Month 24
|
Detection of the first instance of N. gonorrhoeae infection in a urine sample or on a swab taken from the urethra, anorectum, oropharynx or vagina, as determined by nucleic acid amplification (NAAT) testing.
|
From Month 4 to Month 24
|
To compare the overall incidence of all episodes of N. gonorrhoeae infection diagnosed during the study period between the vaccine and placebo arms.
Time Frame: From Month 4 to Month 24
|
To compare the overall incidence of all episodes of N. gonorrhoeae infection diagnosed during the study period between the vaccine and placebo arms, allowing multiple diagnoses of N. gonorrhoeae infection occurred in the same individuals at different time points.
|
From Month 4 to Month 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure the impact of administration of a 2-dose regimen of 4CMenB vaccine on the incidence of the first episode of symptomatic N. gonorrhoeae infection of the urethra, anorectum or vagina.
Time Frame: From Month 4 to Month 24
|
Symptomatic N. gonorrhoeae infection - first instance of the detection of N. gonorrhoeae infection in a urine sample or on a swab taken from the urethra, anorectum or vagina at a study visit when a participant also reports any symptoms at the relevant anatomic site.
|
From Month 4 to Month 24
|
To measure the impact of administration of a 2-dose regimen of 4CMenB vaccine on the incidence of the first episode of asymptomatic N. gonorrhoeae infection of the urethra, anorectum, oropharynx or vagina.
Time Frame: From Month 4 to Month 24
|
Asymptomatic N. gonorrhoeae infection - first instance of the detection of N. gonorrhoeae infection in a urine sample or on a swab taken from the urethra, anorectum, oropharynx or vagina at a study visit when a participant reports no symptoms at the relevant anatomic site.
|
From Month 4 to Month 24
|
To measure the impact of administration of a 2-dose regimen of 4CMenB vaccine on the incidence of first episode of N. gonorrhoeae infection, regardless of symptoms and anatomic sites, by various N. gonorrhoeae strain types (genotype and AMR phenotype).
Time Frame: From Month 4 to Month 24
|
Strain specific (by whole genome sequence or antimicrobial resistance phenotype) - first instance of the detection of N. gonorrhoeae infection in a urine sample or on a swab taken from the urethra, anorectum, oropharynx or vagina, at a study visit.
|
From Month 4 to Month 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate if the N. gonorrhoeae-specific enzyme-linked immunosorbent assay (ELISA) titres increase following 4CMenB vaccination.
Time Frame: From Baseline through to Month 3
|
The enzyme-linked immunosorbent assay (ELISA) of serum and oral mucosal transudates post 4CMenB dose 1 and dose 2, relative to baseline.
|
From Baseline through to Month 3
|
To evaluate if the N. gonorrhoeae-specific serum bactericidal activity assay titres increase following 4CMenB vaccination.
Time Frame: From Baseline through to Month 3
|
The serum bactericidal activity (SBA) titres of serum post 4CMenB dose 1 and dose 2, relative to baseline.
|
From Baseline through to Month 3
|
To evaluate if the serum opsonophagocytic killing assay (OPK) titres increase following 4CMenB vaccination.
Time Frame: From Baseline through to Month 3
|
The opsonophagocytic killing (OPK) titres of serum post 4CMenB dose 1 and dose 2, relative to baseline.
|
From Baseline through to Month 3
|
To evaluate if the N. gonorrhoeae-specific ELISA correlate with reduced N. gonorrhoeae infection.
Time Frame: From Baseline through to Month 24
|
The ELISA titres of serum during the study period.
|
From Baseline through to Month 24
|
To evaluate if the N. gonorrhoeae-specific titres correlate with reduced N. gonorrhoeae infection.
Time Frame: From Baseline through to Month 24
|
The SBA titres of serum during the study period.
|
From Baseline through to Month 24
|
To evaluate if the N. gonorrhoeae-specific OPK titres correlate with reduced N. gonorrhoeae infection.
Time Frame: From Baseline through to Month 24
|
The OPK titres of serum during the study period.
|
From Baseline through to Month 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Professor Kate Seib, BSc(Hon),PhD, Institute for Glycomics, Griffith University, Queensland, Australia
- Principal Investigator: Professor Basil Donovan, MBBS, MD, The Kirby Institute, University of New South Wales Sydney, Australia
- Principal Investigator: Professor Andrew Grulich, MBBS, PhD, The Kirby Institute, University of New South Wales Sydney, Australia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 8, 2021
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
May 19, 2020
First Submitted That Met QC Criteria
June 1, 2020
First Posted (Actual)
June 4, 2020
Study Record Updates
Last Update Posted (Actual)
May 25, 2023
Last Update Submitted That Met QC Criteria
May 23, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Sexually Transmitted Diseases
- Disease Attributes
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Neisseriaceae Infections
- Sexually Transmitted Diseases, Bacterial
- Urogenital Diseases
- Genital Diseases
- Infections
- Communicable Diseases
- Gonorrhea
Other Study ID Numbers
- HEPP2001
- APP1182443 (Other Grant/Funding Number: National Health and Medical Research Council, Australia)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neisseria Gonorrheae Infection
-
Rush University Medical CenterNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsRecruitingBacterial Vaginosis | Trichomonas Vaginitis | Neisseria Gonorrheae Infection | Chlamydia Trachomatis Infection | Vaginal MicrobiomeUnited States, Kenya
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsActive, not recruitingHIV Infections | HIV/AIDS | Neisseria Gonorrheae Infection | Chlamydia Trachomatis Infection | Syphilis InfectionKenya
-
NeuMoDx Molecular, Inc.NAMSACompletedNeisseria Gonorrheae Infection | Chlamydia Trachomatis InfectionUnited States
-
University of North Carolina, Chapel HillCompletedHIV Infections | Infections | RNA Virus Infections | Blood-Borne Infections | Sexually Transmitted Diseases, Viral | Sexually Transmitted Diseases | Sexually Transmitted Diseases, Bacterial | Syphilis | Communicable Disease | Virus Disease | Neisseria Gonorrheae Infection | Chlamydia Trachomatis InfectionMalawi
-
Nova Scotia Health AuthorityDalhousie UniversityNot yet recruitingNeisseria Gonorrheae Infection | Chlamydia Trachomatis InfectionCanada
-
Centre Hospitalier Régional d'OrléansCompletedNeisseria Gonorrheae Infection | Chlamydia Trachomatis Infection | Sensitivity | Mycoplasma Genitalium Infection | Polymerase Chain ReactionFrance
-
University of AdelaideCompletedMeningococcal Infections | Neisseria Infection | Neisseria Meningitis SepsisAustralia
-
Public Health EnglandCompleted
-
University of BernUniversity of Alabama at Birmingham; University of Southern California; Louisiana... and other collaboratorsActive, not recruitingHIV Infections | Premature Birth | Microbial Colonization | Pregnancy; Infection | Bacterial Vaginosis | Trichomonas Vaginitis | Neisseria Gonorrheae Infection | Chlamydia Trachomatis Infection | Mycoplasma Genitalium Infection | Genital Mycoplasma Infection | Vaginal Candida | Sexually Transmitted Infections... and other conditionsSouth Africa
Clinical Trials on 4CMenB vaccine
-
Chinese University of Hong KongRecruitingGonorrhea | Sexually Transmitted InfectionHong Kong
-
University of AdelaideUniversity of Sydney; The University of New South Wales; Menzies School of Health... and other collaboratorsRecruitingGonorrhea | Meningococcal DiseaseAustralia
-
University of OxfordKEMRI-Wellcome Trust Collaborative Research ProgramCompleted
-
University of AdelaideSA HealthCompletedMeningococcal DiseaseAustralia
-
Ospedale Policlinico San MartinoGlaxoSmithKlineCompletedAcquired ImmunodeficiencyItaly
-
St George's, University of LondonGlaxoSmithKline; Public Health England; MeningitisNowCompletedPrematurity | Meningococcal Disease | VaccinationUnited Kingdom
-
University of OxfordImperial College London; Public Health England; Novartis Vaccines; European CommissionCompleted
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedNeisseria Gonorrhoeae InfectionUnited States
-
GlaxoSmithKlineCompleted
-
CHU de Quebec-Universite LavalGlaxoSmithKline; Canadian Immunization Research NetworkCompletedMeningococcal Infections